Monoclonal antibody humanness score and its applications by Sean H Gao et al.
Gao et al. BMC Biotechnology 2013, 13:55
http://www.biomedcentral.com/1472-6750/13/55RESEARCH ARTICLE Open AccessMonoclonal antibody humanness score and its
applications
Sean H Gao, Kexin Huang, Hua Tu and Adam S Adler*Abstract
Background: Monoclonal antibody therapeutics are rapidly gaining in popularity for the treatment of a myriad of
diseases, ranging from cancer to autoimmune diseases and neurological diseases. Multiple forms of antibody
therapeutics are in use today that differ in the amount of human sequence present in both the constant and
variable regions, where antibodies that are more human-like usually have reduced immunogenicity in clinical trials.
Results: Here we present a method to quantify the humanness of the variable region of monoclonal antibodies
and show that this method is able to clearly distinguish human and non-human antibodies with excellent
specificity. After creating and analyzing a database of human antibody sequences, we conducted an in-depth
analysis of the humanness of therapeutic antibodies, and found that increased humanness score is correlated with
decreased immunogenicity of antibodies. We further discovered a surprisingly similarity in the immunogenicity of
fully human antibodies and humanized antibodies that are more human-like based on their humanness score.
Conclusions: Our results reveal that in most cases humanizing an antibody and confirming the humanness of the
final form may be sufficient to eliminate immunogenicity issues to the same extent as using fully human
antibodies. We created a public website to calculate the humanness score of any input antibody sequence based
on our human antibody database. This tool will be of great value during the preclinical drug development process
for new monoclonal antibody therapeutics.
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The first monoclonal antibody therapeutic was approved
for use in the United States in 1986, the mouse anti-
CD3 molecule muromonab that reduces organ trans-
plant rejection [1]. Since then, nearly 30 full-length
therapeutic antibodies and 10 fragment antigen-binding
(Fab) antibodies have been approved in the United States
or Europe, with hundreds more in preclinical and clin-
ical development [2-7]. Therapeutic antibodies are used
in a myriad of disease settings, including oncology, auto-
immune, and neurological disorders. There are four
major antibody types used as therapeutics: fully non-
human (most commonly mouse), chimeric (non-human
variable region, human constant) [8], humanized (human
and non-human variable region sequence, human con-
stant) [9,10], and fully human [4]. Therapeutics have
evolved to include more human sequences, since in* Correspondence: adam.adler@lakepharma.com
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reproduction in any medium, provided the orgeneral the more human sequence that is present in the
antibody, the less immunogenic the antibody will be
once introduced to humans [11]. Immunogenicity refers
to the ability of a therapeutic antibody to induce the for-
mation of anti-drug antibodies (ADAs) when adminis-
trated into a human. ADAs are immune system generated
antibodies against the therapeutic that can reduce the effi-
cacy of the drug, and more importantly they can also
cause adverse effects ranging from a rash at the site of in-
jection to a systemic inflammatory reaction that can be
fatal [12,13]. Therefore it would be extremely valuable to
know whether an antibody may be immunogenic prior to
clinical trials are initiated.
The complementarity determining regions (CDRs) of
an antibody are the most variable segments of the vari-
able domain that are essential for the antibody-antigen
binding specificity and affinity [14]. The CDRs and the
surrounding framework segments comprise the full vari-
able sequence of an antibody. Several attempts have pre-
viously been made to calculate a humanness score of the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for such a tool is to aid in identifying antibody sequences
that are likely to have reduced immunogenicity when in-
troduced to humans. First, Abhinandan and Martin [15]
developed the H-score, which calculates the average
sequence identity of a given antibody sequence as com-
pared to a small database of human variable region se-
quences. Using these data, however, the authors were
unable to find a clear correlation between H-score and
immunogenicity of a small set of therapeutic antibodies.
Second, Pelat et al. [16] defined a germinality index that
is the proportion of framework residues that are identi-
cal between a given antibody variable region sequence
and the closest related human germline sequence. The
score was used to analyze humanized forms of a ma-
caque anthrax toxin antibody. Third, Thullier et al. [17]
developed the G-score, which is similar to the H-score
expect that the score attempts to classify which germline
framework sequence the input antibody was originally
derived from. The authors used this tool to study the
humanness of multiple macaque antibody sequences.
The germinality index only compares sequences to a
single germline sequence, and the databases for the H-
score and G-score were composed of a small set of ~3,500
antibody sequences. Further, after assigning H-scores to a
set of mouse antibody sequences, nearly all mouse heavy
chain sequences scored in the same range as human heavy
chain sequences, and more than half of the mouse light
chains scored in the same range as human light chain se-
quences [15]. If an antibody humanness scoring method is
unable to clearly distinguish a human and mouse se-
quence, it is not possible to definitely state how human a
given sequence really is by these scoring methods. Here
we have developed a new tool to determine the human-
ness of antibody variable region sequences, termed the
T20 score analyzer. After refining the input antibody data-
bases, we found that the T20 score can clearly separate
human sequences from mouse sequences and many other
species as well. The T20 score was used to conduct a
thorough analysis of a large set of therapeutic antibodies,
revealing surprising similarities between human-like hu-
manized antibodies and fully human antibodies. The T20
score analyzer is available for free use online: http://
abAnalyzer.lakepharma.com.
Results
T20 score analyzer development
First, we curated a large database of ~38,700 human anti-
body variable region sequences in order to develop a new
tool to analyze human antibody variable region sequences.
The variable region sequence of antibody sequences were
numbered using the Kabat numbering system [18] and the
CDR and framework regions were annotated. Sequences
for variable heavy chain (VH), variable kappa light chain(VK), and variable lambda light chain (VL) were stored as
full-length sequences or as framework only sequences
(where the CDR regions were removed from the se-
quences) to obtain the All Human Databases (Figure 1A).
Starting with a single input variable region antibody se-
quence (either full-length or framework only VH, VK, or
VL), protein BLAST [19] was performed against all se-
quences in the respective database. Following BLAST the
matching sequences were sorted from high to low based
on the percent identity with the input sequence. The per-
cent identity of the Top 20 matched sequences were aver-
aged to obtain the T20 Score (Figure 1B), where the T20
score is a measurement of how human-like the variable
region of an antibody looks, with 100 being the highest
possible score; most antibodies analyzed with this method
scored at least 40. When the T20 score was obtained for
each sequence from the curated All Human Databases
and then the scores were sorted from high to low, a
relatively normal distribution was observed for both
full-length and framework only sequences (Figure 2A,
Additional file 1: Figure S1A).
An antibody humanness score should possess the abil-
ity to distinguish human antibody sequences from other
species' antibody sequences, such as mouse, with high
specificity. To determine the ability of the T20 score to
differentiate human antibody sequences from mouse, we
scored thousands of mouse antibody sequences with the
T20 score analyzer using the All Human Databases
(Figure 2A, Additional file 1: Figure S1A). Most of the
scores for human and mouse sequences had clear sepa-
ration; however some amount of overlap remained be-
tween human and mouse VH and VK sequences. One
potential reason to explain why many of the mouse se-
quences are scoring higher T20 scores is due to their
similarity with the human sequences that had the lowest
T20 scores, i.e. the mouse sequences could be similar to
the human sequences that looked the least human-like.
If this was correct, we predicted that if the least human-
like sequences were removed from the database and the
mouse sequences were re-scored, this would create a
clearer separation between mouse and human sequences.
To test this, we removed the bottom 15% of human se-
quences from each database to obtain T20 Cutoff Human
Databases (Figure 1C). This created a T20 score cutoff,
which is the T20 score where sequences above this cutoff
are considered human-like. We then re-scored the mouse
sequences using the T20 Cutoff Human Databases and
found a striking reduction in the T20 scores for the
full-length and framework only mouse sequences, with
minimal overlap between human and mouse sequences
(Figure 2B, Additional file 1: Figure S1B). Importantly,
despite removing many human sequences from the data-
bases, re-scoring all human sequences with the refined


























T20 Cutoff Human Databases:
VH: 25,389 sequences (full-length; cutoff = 79)
VH: 25,290 sequences (framework only; cutoff = 84)
VK: 4,309 sequences (full-length; cutoff = 86)
VK: 4,339 sequences (framework only; cutoff = 90)
VL: 3,106 sequences (full-length; cutoff = 84)
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T20 humanness score (average % identity)
T20 score cutoff
[Sequences above cutoff look human-like]
Bottom ~15% sequences
[Removed from T20 Cutoff Human Databases]
Figure 1 T20 analyzer development. (A) Antibody sequence curation. Variable region protein sequences had Kabat numbering applied and
the CDR regions identified. Variable heavy chain (VH), variable light kappa chain (VK), and variable light lambda chain (VL) sequences were
curated into databases as full-length sequences or framework-only sequences (where the CDR regions were removed). The number of unique
antibody sequences in each database is shown. (B) Defining the T20 score. Protein BLAST is used to determine the sequence identity of an input
sequence with each database sequence. The percent identities of the Top 20 matched sequences are averaged to obtain the T20 score for a
given input sequence. (C) Left: Details of obtaining the T20 Cutoff Human Databases. Right: Histogram of the T20 scores of a sample set of
antibody sequences, indicating the T20 score cutoff and the 15% of sequences below this cutoff that were removed to form the T20 Cutoff
Human Database for each chain type. The number of unique antibody sequences in each database is shown.
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humanness analysis tool that focused on the top 85% of
human antibody sequences, we were able to clearly sepa-
rate human and mouse antibody sequences with excellent
specificity, and defined human-like sequences as those
scoring above the T20 score cutoff. From here on, the T20
score only refers to sequences scored with the T20 Cutoff
Human Databases.
T20 score analysis of a collection of antibody sequences
To determine the reproducibility of the T20 score dis-
tinguishing most human and mouse sequences based on
their variable region sequences, an independent set of
human and mouse antibodies were evaluated. For both
full-length sequences (Figure 3A-C) and framework only
sequences (Figure 3D-F), the T20 score was able to ac-
curately classify the vast majority of human sequences ashuman-like and most if not all mouse sequences as not
human-like. This validated the T20 score as a reprodu-
cible method to classify the humanness of an antibody
sequence with high specificity.
We next analyzed the variable regions of human and
mouse germline sequences, and while there was some
variability depending on the chain type being analyzed,
in general the T20 score accurately classified the human
germline sequences as having high T20 scores with the
mouse germline sequences having scores mostly below
the human-like T20 score cutoff; similar trends were
seen for both full-length and framework only germline
sequences (Figure 3). We further found that human anti-
bodies produced in mice that were transgenic for human
IgG genes [20-22] produced human antibodies with high
T20 scores that were similar to germline sequences. By
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Figure 2 T20 scores distinguish human and mouse antibody variable region sequences. (A) T20 scores using All Human Databases. Shown
are histograms of the T20 scores for large sets of human or mouse antibody sequences of the indicated chain type. The T20 score cutoff for each
antibody chain is indicated by the dashed line. (B) Comparing scores using T20 All Human and Cutoff Human Databases. Shown are histograms
of the T20 scores for the same set of human or mouse antibody sequences scored with the indicated database. Note that the human sequences
with scores below the T20 score were removed from these graphs. The percent of mouse antibodies sequences scored with the T20 Cutoff
Human Database that are above the T20 cutoff is provided on the right.
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these data further validate the T20 score as a means to
consistently and accurately classify antibody sequences
as human-like or not.
To determine the humanness of antibody sequences from
other species, T20 scores were calculated for full-length
and framework only sequences for 12 additional species
ranging from fish to non-human primates (Figure 3). Ge-
nerally, the non-human primate antibody sequences had
high T20 scores and thus many of them are difficult to
distinguish from human sequences, with the Rhesus ma-
caque and Chimpanzee having the highest scores. Fish se-
quences showed the lowest T20 scores, while mammals
and amphibians were somewhere in between. No antibody
sequences from non-primates besides mice and rats looked
human-like (Figure 3).The humanness of therapeutic antibodies
We curated a set of 98 mouse, chimeric (from mouse),
humanized, and fully human antibody sequences that
are either approved for clinical use or in various stages
of clinical development. We only focused on antibodies
with kappa light chain sequences since very few thera-
peutic antibodies had lambda light chains. We first de-
termined how well the T20 score could detect changes
in the variable region sequence of therapeutic antibodies
that underwent humanization. Of 22 antibody pairs ana-
lyzed, only the light chain of one sequence showed no
change in the T20 score while all others showed an increase
in their T20 scores upon humanization (Figure 4A). Inter-
estingly, for the full-length sequences after humanization,
half of the antibody sequences looked human-like, despite
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Figure 3 T20 scores of a collection of antibody sequences. T20 scores were obtained for each listed group of antibodies for the indicated
chain type for full-length antibody sequences (A-C) or framework only antibody sequences (D-F). Individual antibody sequences are shown as
small circles, and the average ± SD T20 score is shown for each group. The percent of antibody sequences with T20 scores above their respective
T20 score cutoff (indicated by the dashed line) is provided below each graph. The antibody groups with 85% or more of the sequences above
the cutoff (i.e. they are mostly human-like) are indicated by the blue text. Groups with dashes for the percent value did not have any sequences
represented by the particular chain.

















































































































































































































































































































Heavy chain full-length Light chain full-length Heavy chain framework only
Light chain framework only
Figure 4 (See legend on next page.)
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(See figure on previous page.)
Figure 4 Humanness of therapeutic antibodies. (A) T20 scores are shown for the indicated chain type for 22 therapeutic mouse antibodies
that underwent humanization. Each circle is one antibody, and the lines connect a mouse antibody with its respective humanized antibody. The
T20 score cutoff is indicated by the dashed line. (B-E) Shown are the T20 score (top), H-score (middle), and G-score (bottom) of 98 heavy chain
full-length (B) and kappa light chain full-length (C) sequences for mouse, chimeric, humanized, and fully human therapeutic antibodies. Note that
the H-score and G-score are scaled based on Z-scores. The T20 score of heavy chain framework only (D) and kappa light chain framework only
(E) sequences are presented. Each antibody is a circle, and the average ± SD T20 score is provided for each group. The T20 score cutoff is
indicated by the dashed line. Select groups of antibodies were compared using Student’s t-tests, and the P-values of significance are listed for
each comparison.
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nearly all humanized antibodies had framework sequences
that looked human-like. This was generally expected since
human germline framework sequences are typically uti-
lized as donor sequences for the humanization process
[10], and most germline sequences have very high T20
scores (Figure 3D-E).
We next calculated the average T20 score for each
type of therapeutic antibody. As anticipated the human-
ness of mouse and chimeric antibodies were nearly
identical for both full-length and framework only se-
quences (Figure 4B-E). For full-length sequences, the hu-
manness of humanized heavy and light chain sequences
increased strongly, and the T20 score analyzer was sensi-
tive enough to detect a further significant increase in the
humanness of fully human antibodies (Figure 4B-C). In
contrast for framework only sequences, the humanness
of both humanized and human sequences were very
similar (Figure 4D-E).
To compare the effectiveness of the T20 score to clas-
sify the humanness of antibodies as compared to other
antibody humanness scoring tools, we determined the
H-score [15] and G-score [17] for the 98 therapeutic
antibodies. When the T20 score and H-score or G-score
were directly compared for the same antibody sequences,
the scores were positively correlated for both heavy and
light chain sequences (P<10-20 for each comparison;
Additional file 3: Figure S3). Despite the positive corre-
lation with the T20 score, the H-score and G-score were
unable to separate the humanness of the therapeutic anti-
body groups as well as the T20 score (Figure 4B-C). In
particular the differences between mouse/chimeric and
humanized or human antibodies, and the differences be-
tween humanized and human sequences, were much less
significant with the H-score or G-score as compared to
the T20 score. And although the average H-score and G-
score for human antibodies were trending higher than
humanized antibodies, when individual sequences were
analyzed separate from their group, these scoring methods
were not able to clearly distinguish most of the humanized
antibodies from fully human antibodies to the same extent
as the T20 score (Figure 4B-C). These data reveal that the
T20 score is more reliable at classifying antibodies ashuman-like with better specificity than alternative anti-
body humanness analysis tools.
Correlation of humanness and immunogenicity of
therapeutic antibodies
Of the 98 therapeutic antibodies curated above, 65 of
them had available data on the antibody immunogenicity
from human clinical trials ([11,23,24] and references
within). When the T20 scores of all therapeutic antibodies
were directly compared to their immunogenicity, there
was a clear negative correlation for both full-length and
framework only sequences: the higher the T20 score, the
lower the immunogenicity of the antibody (Figure 5A,
Additional file 4: Figure S4A). When these antibodies were
separated into the respective antibody class, specific
patterns emerged that were similar for full-length and
framework only, heavy and light chain sequences. Al-
though mouse and chimeric antibodies had similar T20
scores, on average there was a strong decrease in the im-
munogenicity of chimeric antibodies compared to mouse
(Figure 5B-C, Additional file 4: Figure S4B-C). A further
increase in T20 score seen with humanized antibodies
resulted in a further drop in the immunogenicity. And al-
though fully human antibodies have an even further in-
crease in T20 score for full-length antibody sequences
compared to humanized antibodies, there was little subse-
quent decrease in their immunogenicity (Figure 5B-C).
One exception was the humanized antibody daclizumab
that had a strong immunogenic response in 24% of pa-
tients (antibody indicated by the arrow in Figure 5B);
when this antibody was removed from the analysis, the
minor difference in the immunogenicity of humanized
and human antibodies disappeared (Additional file 5:
Figure S5). These data suggest that because the immuno-
genicity of humanized and fully human antibodies are
nearly identical, with minor exceptions, there may not be
an extra benefit of obtaining fully human therapeutic anti-
bodies as long as the humanized antibody has a higher
T20 score than its mouse/chimeric parental sequence.
The benefit of performing antibody humanization was
further evidenced by following the humanness and im-
munogenicity of therapeutic antibodies prior to and after
humanization. Within our curated therapeutic antibody
htgnel-llufniahcthgiLhtgnel-llufniahcyvaeH





































































































































































































Figure 5 Associating immunogenicity and humanness score of therapeutic antibodies. (A) The immunogenicity (percent of patients that
had antibodies against the therapeutic antibody itself) and T20 score of 65 therapeutic antibodies (full-length heavy chains on the left, kappa
light chains on the right) were graphed together, and Pearson correlations were calculated (red-dashed line; R2). P-values are one-sided t-tests.
(B) The same data from (A) is shown with the antibody type indicated by different colors. Trend lines for each group are shown in their
respective color. The arrow points to the humanized antibody daclizumab that is referenced in the main text. (C) The black bars are the average
± SD immunogenicity of the indicated group of antibodies; the gray bars show the average ± SD T20 score.
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http://www.biomedcentral.com/1472-6750/13/55database, there were three mouse antibodies that under-
went humanization and were included in clinical trials
as both mouse and humanized antibodies. All three mouse
antibodies initially had high levels of immunogenicity with
low T20 scores (Figure 6). The humanness of the antibody
heavy and light chain sequences increased following
humanization, and this increase correlated with a shift to
no detectable immunogenicity in all three cases, under-
scoring the critical importance of performing antibody
humanization prior to conducting clinical trials. The
data suggest that the framework only T20 score of thehumanized heavy and light chains should be equal to or
above the T20 score cutoff (i.e. they are human-like). In
contrast, the full-length sequence appears to only need
to increase its humanness T20 score, as it does not
have to look human-like in order to benefit from anti-
body humanization and have similar immunogenic
properties as a fully human antibody. Therefore quanti-
fying the humanness of therapeutic antibody sequences
with the T20 score analyzer is a powerful tool that can




























































































































Figure 6 Immunogenicity of therapeutic antibodies before and after humanization. The immunogenicity and T20 score of three mouse
therapeutic antibodies before and after humanization are shown for the indicated chain type. The arrows show the change in immunogenicity
and T20 score of the mouse antibody after humanization.
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A critical issue with therapeutic antibodies in the clinic
is reducing the potential immunogenicity of the final
therapeutic form [23]. One of the more recent tactics to
avoid possible immunogenicity issues is by using fully hu-
man antibodies, either produced in transgenic mice [22]
or using phage display technology [25], which are often
difficult processes compared to traditional monoclonal
antibody development [4]. Data presented here revealed
that despite a significant difference in the humanness of
humanized and fully human antibody sequences, with
minor exceptions the immunogenicity of the antibodies
was nearly indistinguishable. This was shown in detail for
three antibodies that started with high levels of immuno-
genicity as mouse antibodies, and after their humanization
they became non-immunogenic antibodies; the decreased
immunogenicity was correlated with an increase in the
humanness score of both the heavy and light chains of
each antibody. Therefore an additional mechanism to de-
crease the chance of a humanized antibody being im-
munogenic in humans is verifying that both the heavy and
light chains of the humanized antibody have increasedT20 scores over the parental sequence and are thus more
human-like. While it is possible that humanized anti-
bodies with lower T20 score will not be immunogenic in
the clinic, in general non-human-like antibodies were
associated with increased immunogenicity (Figure 5A).
The unique ability of the T20 score analyzer to specif-
ically determine the humanness of the framework re-
gions of an antibody sequence is especially useful when
performing antibody humanization, where the CDR se-
quences are purposely left as parental sequences and
only the framework region is transformed into a human-
like sequence. For example, the humanness of an anti-
body framework sequence can be followed throughout
the process of performing humanization, where each
subsequent change to the framework region can be scored
and tracked. Our own antibody humanization efforts re-
vealed that despite the high T20 scores for most donor
human germline framework sequences (Figure 3D), re-
introducing specific parental framework sequences into a
human germline sequence is sometimes sufficient to re-
vert the T20 score of the humanized framework sequence
to the same score as the initial parental framework
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score analyzer would be simple to implement during the
therapeutic antibody development process, it can be used
to prevent antibody sequences with low humanness scores
from progressing along the pipeline.
Other methods have been developed to predict anti-
body immunogenicity, such as experimentally screening
molecules for antigen specific activation of T-cells or ex-
perimentally searching for T-cell epitopes followed by
their removal through targeted substations [23,26]. How-
ever these methods require a combination of in vitro ex-
perimentation in addition to in silico prediction tools.
We propose that these complicated and time-consuming
methods are not necessary since it appears that increa-
sing the humanness of the variable region sequence is
sufficient to remove most cases of immunogenicity,
which can be directly monitored with the T20 score
analyzer.
Researchers have utilized phage display technologies
to express synthetic repertoires of antibodies that can be
screened for binding to specific antigens [27-29]. During
the screening process it would be useful to predict
whether these synthetic antibodies would be immuno-
genic in humans or not, for example by utilizing the T20
score to analyze the sequences. We used the T20 score
analyzer to determine the humanness score of a small set
of synthetic antibodies and compared these to human
antibodies. Surprisingly, the average and range of T20
scores observed for the variable regions of synthetic anti-
bodies was very similar to human antibodies (Additional
file 7: Figure S7). Due to the absence of immunogenicity
data from synthetic antibodies, we were unable to directly
correlate the T20 score of synthetic antibodies with im-
munogenicity. However since the T20 scores of syn-
thetic and human antibodies are similar, we suggest that
the T20 score may be able to predict the immunoge-
nicity of synthetic antibodies to a similar extent as hu-
man antibodies.
Conclusion
Here we have developed the T20 score analyzer to cal-
culate the humanness of variable region sequences of
monoclonal antibodies with high specificity and repro-
ducibility. In addition to providing a score for the full-
length antibody sequence of heavy, kappa light, and
lambda light chains, the tool can exclude the CDR re-
gions to calculate a separate score focusing only on the
framework regions. We used this tool to study thera-
peutic antibodies that have been approved for clinical
use or are currently in clinical development. Of note
we observed consistent decreases in the immunoge-
nicity of antibodies that underwent humanization that
resulted in increased T20 scores, suggesting that the
T20 score may be used as a metric to determinewhether an antibody has been truly humanized. We
further found that the T20 score analyzer was better at
assessing the differences in the humanness of thera-
peutic antibodies compared to previously published
humanness scoring methods. This tool will be a valu-
able asset to accurately measure the humanness of the
variable region of new therapeutic antibodies during
their preclinical development.
Methods
Antibody variable region sequence curation
For the All Human Databases, antibody variable region
protein sequences were obtained from NCBI IgBLAST
(http://www.ncbi.nlm.nih.gov/igblast/retrieveig.html). Se-
quences were obtained and processed in high-throughput
using scripts written in Python. Variable heavy chain
(VH), kappa light chain (VK), and lambda light chain (VL)
sequences were downloaded separately. Synthetic Ig mole-
cules were excluded, and the minimum sequence length
was set to 90 amino acids. Sequences were assigned Kabat
numbering using the Abnum tool [30] and CDR residues
were identified following the guidelines put forth by Kabat
[18]. Sequences that Abnum was unable to assign the
numbering scheme to were excluded from further ana-
lysis. Duplicate sequences were removed prior to forming
the final databases, and sequences mislabeled as ‘human’
humanized antibodies or human antibodies obtained from
transgenic mice were also excluded. In total 29,958 heavy
chain sequences, 5,042 kappa light chain sequences, and
3,708 lambda light chain sequences were curated for the
All Human Databases.
The mouse protein sequences used to validate the hu-
man databases were also obtained from NCBI IgBLAST
and processed in the same way as the human sequences.
In total 11,781 heavy chain sequences, 3,652 kappa light
chain sequences, and 357 lambda light chain sequences
were curated.
The human and mouse germline sequences were
obtained from NCBI IgBLAST (http://www.ncbi.nlm.
nih.gov/igblast/showGermline.cgi). Human antibodies
from transgenic mice were selected from the human
sequences downloaded from IgBLST described above
based on the descriptions found in the NCBI protein
database (http://www.ncbi.nlm.nih.gov/protein). The in-
dependent set of human and mouse antibody sequences
were obtained from Abysis database (http://www.bioinf.
org.uk/abysis); these were compared to the sequences in
the All Human Databases to remove any overlapping se-
quences. The antibody sequences for the remaining spe-
cies and synthetic antibodies were obtained from Abysis
and/or NCBI protein database. Sequences for the thera-
peutic antibodies were obtained from United States pa-
tent applications (patft.uspto.gov) and the KEGG drug
database (http://www.genome.jp/kegg/drug).
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An input VH, VK, or VL variable region protein sequence
is first assigned Kabat numbering and CDR residues are
identified. The full-length sequence or the framework only
sequence (with CDR residues removed) is compared to
every sequence in the respective antibody database using
the blastp protein-protein BLAST algorithm [19]. The se-
quence identity between each pairwise comparison is iso-
lated, and after every sequence in the database has been
analyzed, the sequences are sorted from high to low based
on the sequence identity to the input sequence. The per-
cent identity of the Top 20 matched sequences is averaged
to obtain the T20 score. The T20 score analyzer was
coded entirely using Python.
Formation of T20 cutoff human databases
For each chain type (VH, VK, VL) and sequence length
(full-length or framework only) in the All Human Data-
bases, each antibody sequence was scored with its re-
spective database using the T20 score analyzer. The T20
score was obtained for the top 20 matched sequences
after the input sequence itself was excluded (the percent
identity of sequences 2 through 21 were averaged since
sequence 1 was always the input antibody itself ). The
T20 scores for each group were sorted from high to low.
The decrease in score was roughly linear for most of the
sequences; however the T20 scores for the bottom ~15%
of antibodies started decreasing sharply. Therefore the
bottom 15 percent of sequences were removed and the
remaining sequences formed the T20 Cutoff Human Da-
tabases, where the T20 score cutoff indicates the lowest
T20 score of a sequence in the new database. The exact
number of antibody sequences in each database for full-
length and framework only is provided in Figure 1C; note
that the numbers are slightly different for full-length and
framework only sequences since the T20 score cutoff was
rounded to the nearest whole number closest to the
bottom 15th percentile sequence. A web-based tool is pro-
vided to calculate the T20 score of antibody sequences
using the T20 Cutoff Human Databases: http://abAnalyzer.
lakepharma.com.
Additional files
Additional file 1: Figure S1. T20 scores distinguish human and mouse
antibody framework sequences. (A) T20 scores using All Human
Databases. Shown are histograms of the T20 scores for large sets of
human or mouse antibody sequences of the indicated chain type. The
T20 score cutoff for each antibody chain is indicated by the dashed line.
(B) Comparing scores using T20 All Human and Cutoff Human Databases.
Shown are histograms of the T20 scores for the same set of human or
mouse antibody sequences scored with the indicated database. Note
that the human sequences with scores below the T20 score were
removed from these graphs. The percent of mouse antibodies sequences
scored with the T20 Cutoff Human Database that are above the T20
cutoff is provided on the right.Additional file 2: Figure S2. Comparing human sequences with All
Human and T20 Cutoff Human Databases. Shown are histograms of the
T20 scores for all human antibody sequences of the indicated chain type
comparing the scores obtained using the indicated scoring database.
Human sequences were separated into two groups, either above (red) or
below (green) the T20 score cutoff using the All Human Databases. Each
of the two groups of sequences was then scored with the T20 Cutoff
Human Database, and the change in the T20 scores is shown separately
for the sequences above (purple) or below (blue) the T20 score cutoff.
Additional file 3: Figure S3. Comparison of T20 score with H-score
and G-score. T20 scores, H-scores, and G-scores were obtained for 98
heavy chain full-length (top) and kappa light chain full-length (bottom)
therapeutic antibody sequences. Note that the H-score and G-score are
scaled based on Z-scores. T20 scores were directly compared to H-scores
(left) or G-scores (right), and Pearson correlations were calculated (red-
dashed line; R2). P-values are one-sided t-tests.
Additional file 4: Figure S4. Associating immunogenicity and
humanness score of therapeutic antibodies. (A) The immunogenicity and
T20 score of 65 therapeutic antibodies (framework only heavy chains on
the left, kappa light chains on the right) were graphed together, and
Pearson correlations were calculated (red-dashed line; R2). P-values are
one-sided t-tests. (B) The same data from (A) is shown, with the antibody
type indicated by different colors. Trend lines for each group are shown
in their respective color. (C) The black bars are the average ± SD
immunogenicity of the indicated group of antibodies; the gray bars show
the average ± SD T20 score.
Additional file 5: Figure S5. No difference in immunogenicity of
humanized and human antibodies after removing daclizumab. The black
bars are the average ± SD immunogenicity of all human and humanized
antibodies; the gray bars show the average ± SD immunogenicity of all
human antibodies and humanized antibodies without daclizumab.
Additional file 6: Figure S6. Humanization of germline frameworks can
revert the humanness of sequences back to the level of the parental
antibody. Shown are the T20 scores of a heavy chain antibody that was
humanized utilizing donor human germline framework sequences. The
parental antibody sequence and three humanized versions with
increasing number of re-introduced parental framework amino acids are
shown. Note that the humanized version 3 sequence that contains the
most parental framework sequence has identical T20 score to the
parental sequence, despite the fact that the majority of the humanized
sequence is still the human framework sequence.
Additional file 7: Figure S7. No difference in T20 score of human
antibodies and synthetic antibodies. T20 scores were obtained for each
listed group of antibodies for the indicated chain type for full-length
antibody sequences. Individual antibody sequences are shown as small
circles, and the average ± SD T20 score is shown for each group.Competing interests
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